Transcriptome analysis of iBET-151, a BET inhibitor alone and in combination with paclitaxel in gastric cancer cells |
Kang, Sun Kyoung
(Songdang Institute for Cancer Research, Yonsei University College of Medicine)
Bae, Hyun Joo (Songdang Institute for Cancer Research, Yonsei University College of Medicine) Kwon, Woo Sun (Songdang Institute for Cancer Research, Yonsei University College of Medicine) Che, Jingmin (Songdang Institute for Cancer Research, Yonsei University College of Medicine) Kim, Tae Soo (Songdang Institute for Cancer Research, Yonsei University College of Medicine) Chung, Hyun Cheol (Songdang Institute for Cancer Research, Yonsei University College of Medicine) Rha, Sun Young (Songdang Institute for Cancer Research, Yonsei University College of Medicine) |
1 | Orenay-Boyacioglu S, Kasap E, Gerceker E, Yuceyar H, Demirci U, Bilgic F, et al. Expression profiles of histone modification genes in gastric cancer progression. Mol Biol Rep 2018;45:2275-2282. DOI |
2 | Kasai S, Sasaki T, Watanabe A, Nishiya M, Yasuhira S, Shibazaki M, et al. Bcl-2/Bcl-xL inhibitor ABT-737 sensitizes pancreatic ductal adenocarcinoma to paclitaxel-induced cell death. Oncol Lett 2017;14:903-908. DOI |
3 | Costa-Silva J, Domingues D, Lopes FM. RNA-Seq differential expression analysis: an extended review and a software tool. PLoS One 2017;12:e0190152. DOI |
4 | Zhu Z, Chen D, Zhang W, Zhao J, Zhi L, Huang F, et al. Modulation of alternative splicing induced by paclitaxel in human lung cancer. Cell Death Dis 2018;9:491. DOI |
5 | Huang G, Zhu G. Sirtuin-4 (SIRT4), a therapeutic target with oncogenic and tumor-suppressive activity in cancer. Onco Targets Ther 2018;11:3395-3400. DOI |
6 | Kurimchak AM, Shelton C, Duncan KE, Johnson KJ, Brown J, O'Brien S, et al. Resistance to BET bromodomain inhibitors is mediated by Kinome reprogramming in ovarian cancer. Cell Rep 2016;16:1273-1286. DOI |
7 | Hong S, Won YJ, Park YR, Jung KW, Kong HJ, Lee ES, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2017. Cancer Res Treat 2020;52:335-350. DOI |
8 | Chua V, Orloff M, Teh JL, Sugase T, Liao C, Purwin TJ, et al. Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma. EMBO Mol Med 2019;11:e9081. |
9 | Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S. Gastric adenocarcinoma. Nat Rev Dis Primers 2017;3:17036. DOI |
10 | Fu DG. Epigenetic alterations in gastric cancer (review). Mol Med Rep 2015;12:3223-3230. DOI |
11 | Shitara K, Ozguroglu M, Bang YJ, Di Bartolomeo M, Mandala M, Ryu MH, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 2018;392:123-133. DOI |
12 | Ahn HK, Jang J, Lee J, Se Hoon P, Park JO, Park YS, et al. P21-activated kinase 4 overexpression in metastatic gastric cancer patients. Transl Oncol 2011;4:345-349. DOI |
13 | Chia DK, So JB. Recent advances in intra-peritoneal chemotherapy for gastric cancer. J Gastric Cancer 2020;20:115-126. DOI |
14 | Bang YJ, Xu RH, Chin K, Lee KW, Park SH, Rha SY, et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18:1637-1651. DOI |
15 | Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean Practice Guideline for Gastric Cancer 2018: an evidence-based, multi-disciplinary approach. J Gastric Cancer 2019;19:1-48. DOI |
16 | Kim HJ, Kang SK, Kwon WS, Kim TS, Jeong I, Jeung HC, et al. Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor. Int J Cancer 2018;143:151-159. DOI |
17 | Shi J, Mitchison TJ. Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic. Endocr Relat Cancer 2017;24:T83-T96. DOI |
18 | Ang YL, Yong WP, Tan P. Translating gastric cancer genomics into targeted therapies. Crit Rev Oncol Hematol 2016;100:141-146. DOI |
19 | Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15:1224-1235. DOI |